Akebia Therapeutics, Inc.
Akebia Therapeutics develops and commercializes therapeutics for kidney diseases. Lead product Vafseo (vadadustat) treats anemia due to chronic kidney disease in dialysis-dependent and non-dialysis patients. Offers Auryxia for serum phosphorus level control and iron deficiency anemia treatment. Product pipeline includes AKB-9090 for critical-care indications and AKB-10108 for premature birth-related conditions. Has collaborations with Mitsubishi Tanabe Pharma and Janssen Pharmaceutica NV. Incorporated in 2007, headquartered in Cambridge, Massachusetts.
Overview
Strengths
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/FCF 1.8x vs. a median of 21.4x and EV/EBITDA 5.4x vs. a median of 12.9x.
- ROIC of 27.9% beats 95% of its 55 Drug Manufacturers - Specialty & Generic peers (median 10.9%).
- Cheaper than its own history: P/FCF 1.8x vs. a historical average of 87.3x and EV/EBITDA 5.4x vs. a historical average of 89.8x.
- Paying down debt: long-term debt fell by 4.7 percentage points of total assets last year.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 13.0% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 7 years.
- Unstable profitability: operating margin ranged from -128% to 10% over the last 7 years, with operating losses in 6 of them.
Key Financial Data